Mediwound Stock

Mediwound EBIT

The EBIT of Mediwound (MDWD) as of Aug 7, 2026 is -25.28 M USD. In the previous year, EBIT was -29.41 M USD — a change of -14.05% (higher).

EBIT

-25.28 MUSD

YoY

-14.05%

Last updated:

In 2026, Mediwound's EBIT was -25.28 M USD, a -14.05% increase from the -29.41 M USD EBIT recorded in the previous year.

The Mediwound EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT (M USD)
Date
EBIT (M USD)
Jan 1, 2023
-15.50 base
Jan 1, 2024
-29.41 base
Jan 1, 2025
-25.28 base
Jan 1, 2026 (e)
-17.34 base
Jan 1, 2027 (e)
-23.63 base
Jan 1, 2028 (e)
-36.04 base
Jan 1, 2029 (e)
-78.14 base
Jan 1, 2030 (e)
-121.10 base
YEAREBIT (M USD)
2030 est -121.10
2029 est -78.14
2028 est -36.04
2027 est -23.63
2026 est -17.34
2025 -25.28
2024 -29.41
2023 -15.50
2022 -7.66
2021 -12.44
2020 -8.73
2019 4.49
2018 -4.77
2017 -13.71
2016 -20.16
2015 -21.23
2014 -21.43
2013 -7.58
2012 -2.73
2011 -4.29
Access this data via the Eulerpool API

Mediwound Revenue

Mediwound Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
18.69 M USD
-15.50 M USD
-6.72 M USD
Jan 1, 2024
20.22 M USD
-29.41 M USD
-30.22 M USD
Jan 1, 2025
16.96 M USD
-25.28 M USD
-23.88 M USD
Jan 1, 2026 (e)
24.13 M USD
-17.34 M USD
-29.64 M USD
Jan 1, 2027 (e)
32.87 M USD
-23.63 M USD
-27.35 M USD
Jan 1, 2028 (e)
50.13 M USD
-36.04 M USD
-14.59 M USD
Jan 1, 2029 (e)
108.69 M USD
-78.14 M USD
7.96 M USD
Jan 1, 2030 (e)
168.44 M USD
-121.10 M USD
30.69 M USD

Mediwound Margins

Mediwound stock margins

The Mediwound margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Mediwound. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Mediwound.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2023
19.15 %
-82.96 %
-35.94 %
Jan 1, 2024
13.03 %
-145.44 %
-149.46 %
Jan 1, 2025
19.19 %
-149.06 %
-140.80 %
Jan 1, 2026 (e)
19.19 %
-71.89 %
-122.85 %
Jan 1, 2027 (e)
19.19 %
-71.89 %
-83.19 %
Jan 1, 2028 (e)
19.19 %
-71.89 %
-29.11 %
Jan 1, 2029 (e)
19.19 %
-71.89 %
7.32 %
Jan 1, 2030 (e)
19.19 %
-71.89 %
18.22 %

Mediwound Stock analysis

What does Mediwound do? Mediwound Ltd is an Israeli company specializing in the development and marketing of therapies for chronic and acute wounds. The company was founded in 2000 and is headquartered in Yavne, Israel. Its history began with the idea of developing an innovative treatment method for burns. The company collaborated closely with the Israeli Ministry of Defense to find a better method for wound treatment. The result was the product NexoBrid, an enzymatic debridement treatment that aims to remove dead tissue from burn wounds to enable faster healing. Mediwound's business model is to develop and market innovative drugs and therapy solutions for wounds. The company operates in several areas, including burn wounds, chronic wounds, and trauma wounds. In the burn wounds sector, Mediwound offers the product NexoBrid, which enzymatically removes dead tissue from burns and eliminates neurotoxic substances that can damage wound healing if left in the tissue for too long. NexoBrid is already approved in several countries, including the USA and European countries. In the chronic wounds sector, Mediwound offers the product EscharEx, which is used to treat chronic wounds such as pressure ulcers, diabetic foot ulcers, and venous leg ulcers. EscharEx also uses an enzymatic approach and aims to remove dead tissue to enable the body's natural healing process. There are plans to launch EscharEx in Europe in the second half of 2021. Mediwound also operates in the trauma wounds sector and received the product MWPC003 in Europe in 2020. It is a novel enzymatic debriding product that can be used in the integrated therapy of complex trauma wounds with additional topical treatment options. Through the development of innovative therapies and drugs, Mediwound has established itself as a reliable partner in wound treatment. The company continues to focus on innovation and plans to expand its product range in the future. Overall, Mediwound Ltd is a groundbreaking company in the field of wound care. The company's products and solutions contribute to faster and more effective wound healing, improving the lives of patients worldwide. Mediwound is one of the most popular companies on Eulerpool.

EBIT Details

Analyzing Mediwound's EBIT

Mediwound's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Mediwound's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Mediwound's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Mediwound’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Mediwound stock

EBIT of Mediwound is -25.28 M USD in 2026.

EBIT of Mediwound changed from -29.41 M USD to -25.28 M USD, representing a -14.05% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT Mediwound since 2006 – with annual values, charts, and detailed analysis.

"Earnings before interest and taxes", abbreviated as EBIT, is also referred to as the operating result of a company. It is a key figure that allows the profit to be assessed over a specific period of time, usually a fiscal year. Taxes and interest are not deducted from EBIT, making it suitable for international comparisons of different companies.

Net income
+ Tax expense
+ Interest expense and other financial expenses
- Interest income and other financial income
= EBIT (operating profit)

EBIT's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT's Mediwound historically and in real time.

The sales revenue is important for evaluating a stock.

EBIT is an acronym for "Earnings Before Interest and Tax" and represents a company's gross profit before taxes and interest are deducted. The EBIT amount is often used as a metric to evaluate a company.

History

The EBIT was originally introduced in the 1940s when the US Internal Revenue Service (IRS) passed a new tax law. This law required companies to calculate their profit before deducting taxes and interest on loans (or "interest and taxes"). Since then, the EBIT has been used as one of the key financial indicators in evaluating a company.

Usage

The EBIT can be used to assess a company by comparing its financial results to a benchmark or a comparative value. The EBIT is also used to determine how much the company's shareholders will receive from its operating income.

Calculation

EBIT is calculated by deducting taxes and interest on loans from the company's net profit. This amount can be calculated in various ways, but the most common method is as follows:

EBIT = Net profit + interest and taxes

Example: Eulerpool: Your source for quantitative stock data At Eulerpool, we are dedicated to providing you with comprehensive and accurate stock information. Our website offers a wide range of tools and features, including charts, stock lists, and more. Whether you are an experienced investor or just starting out, our platform is designed to meet your needs. With our in-depth analytics and algorithms, you can make informed decisions and stay ahead of the market. Explore our extensive collection of stocks, track their performance, and access real-time data. With Eulerpool, you can easily navigate the world of finance and monitor the stocks that matter to you. Join our community today and gain valuable insights into the world of stocks and investments. Sign up for free and discover the power of Eulerpool. Stay informed. Stay ahead. Eulerpool - your trusted partner in stock data.
Net profit of XYZ Co. = $1,000,000
Interest and taxes = $ 500,000
EBIT of XYZ Co. = $1,500,000

Application

The EBIT value is often used to determine and evaluate the financial stability of a company. The EBIT value can also be used to determine how much money a company can spend on investments or dividends.

Use of EBIT in stock investment

Investors use EBIT to determine if a stock is over- or undervalued. If a company has a high EBIT value, it may indicate that its stock is overvalued, as the profit it generates could be lower than what it would generate with a different stock.

Advantages of EBIT

EBIT is a helpful measure for determining the financial stability of a company. There are several advantages associated with using EBIT, such as:
- EBIT eliminates the impact of financing on the company's earnings.
- It is a useful measure for determining the profits that a company can distribute to its shareholders.
- It can be used to determine whether a stock is overvalued or undervalued.

Disadvantages of EBIT

There are also some disadvantages to using EBIT, such as:
- EBIT cannot be used as the sole measure to evaluate a company as it does not reflect the overall profit of the company.
- EBIT can be influenced by unforeseen events such as a tax increase.
- EBIT is not always a reliable indicator of a company's future profit development.

Conclusion

The EBIT is an important measure used to evaluate a company. It can be used to determine how much money a company can generate from its operational results and whether a stock is overvalued or undervalued. However, the EBIT also has some disadvantages as it does not reflect the overall profitability of a company and can be influenced by unforeseen events. Therefore, it is important to consider the EBIT in conjunction with other financial indicators to obtain a complete picture of the company.

Access this data via the Eulerpool API

Income Statement — Mediwound

All Key Metrics — Mediwound